FOR IMMEDIATE RELEASE

Caris Life Sciences to Present Key Research Findings at the European Society for Medical Oncology 2016 Congress

Comprehensive Tumor Profiling with Caris Molecular Intelligence Continues to Yield Molecular Insights to Enable the Delivery of Personalized Medicine

IRVING, Texas, Oct. 06, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today that the Company will deliver five poster presentations, including two poster discussions, at the European Society for Medical Oncology (ESMO) 2016 congress from October 7-11, 2016 in Copenhagen, Denmark.

The studies presented utilized Caris Molecular Intelligence®, the company’s patented and proprietary tumor profiling offering, to help physicians make informed cancer treatment decisions. The use of Caris Molecular Intelligence enabled investigators to identify the biological heterogeneity and molecular characterization of certain types of cancers and inform physicians on therapeutic options, including therapies with potential benefit to consider and, just as important, therapies to avoid due to potential lack of benefit.

Following is a schedule of Caris Life Sciences’ poster presentations:

Title: Molecular characteristics of hepatocellular carcinomas (HCC) from different age groups
Date/Time: Saturday, October 8, 2016 from 8-9 a.m. CET
Abstract: 618PD
Location: Copenhagen meeting room
Collaborators: Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Georgetown University Hospital, Washington, DC; Fox Chase Cancer Center, Philadelphia, PA; Karmanos Cancer institute, Detroit, MI

Title: Comparative molecular analyses of pancreatic cancer (PC): Younger vs. older patients (pts)
Date/Time: Saturday, October 8, 2016 from 8-9 a.m. CET
Abstract: 620PD
Location: Copenhagen meeting room
Authors: M. Salem, P. Philip, R. Feldman, J. Hwang, M. Pishvaian, J. Xiu, W. El-Deiry, S. Reddy,
**Title:** Molecular characterization and comparison of epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PCC)

**Date/Time:** Saturday, October 8, 2016 from 1-2 p.m. CET

**Abstract:** 880P

**Location:** Hall E

**Authors:** A.M. Knipprath, D. Arguello, K. Russell, A. Voss, V. Heinzelmann-Schwarz

**Collaborators:** University Hospital Basel, Switzerland

---

**Title:** PD-L1 status in refractory lymphomas

**Date/Time:** Saturday, October 8, 2016 from 1-2 p.m. CET

**Abstract:** 921P

**Location:** Hall E


**Collaborators:** University Clinical Center, Sarajevo, Bosnia and Herzegovina; Cancer Treatment Center, Santa Clara, CA; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

---

**Title:** Molecular profiling of locally advanced/metastatic olfactory neuroblastomas

**Date/Time:** Sunday, October 9, 2016 from 1-2 p.m. CET

**Abstract:** 964P

**Location:** Hall E

**Authors:** Z. Gatalica, A. Ghazalpour, J. Swensen, R. Bender, S. Vranic, R. Feldman, S. Reddy

**Collaborators:** University Clinical Center, Sarajevo, Bosnia and Herzegovina

---

**About Caris Life Sciences**

Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. With more than 100,000 clinical cases, Caris Molecular Intelligence® (CMI), the company’s patented and proprietary product offering, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Caris Molecular Intelligence uses a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor. CMI then connects the biomarker data generated from the tumor with biomarker-drug associations supported by the evidence and in relevant clinical literature through the Company’s proprietary bioinformatics rules engine. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients utilizing CMI, and has observed that patients treated with drugs consistent with CMI’s recommendations based upon the patient’s tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit [www.CarisLifeSciences.com](http://www.CarisLifeSciences.com).
Media Inquiries:
Brian Stengle
Caris Life Sciences
Media Relations & Corporate Affairs
CorpComm@carisls.com
214-294-5606